CEO Frank Lee indicated that Pacira entered 2025 with significant uncertainty around EXPAREL’s exclusivity, inconsistent margins, and pipeline visibility, but now reports "a clear strategic direction, ...
The presentation emphasized Pacira’s 5x30 growth strategy and significant patent litigation settlement for EXPAREL, which establishes exclusivity through 2039. This comes as the company positions ...
Pacira BioSciences, Inc. has announced a $300 million share repurchase authorization as part of its commitment to enhancing shareholder value and advancing its strategic 5x30 plan, which aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results